MedTrace Logo

Phase I Study of Lenalidomide in Patients With Acute Leukemia

NCT01615042 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-05-28

No results posted yet for this study

Summary

Lenalidomide is a drug that alters the immune system and it may also be directly toxic to tumor. Therefore, in theory, it may reduce or prevent the growth of cancer cells or directly kill them. We will be studying how lenalidomide can be used to decrease bone marrow blast cells in preparation for a bone transplant.

Conditions

Interventions

DRUG

Lenalidomide

Oral capsule, daily, 50mg-100mg, one cycle (21 days)

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Mehrdad Abedi, MD

    lead OTHER

Principal Investigators

  • Mehrdad Abedi, MD · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2017-05-31
Completion
2017-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01615042 on ClinicalTrials.gov